Evolving First-Line Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer: CDK4/6 Inhibition, Biomarker-Guided Strategies and Emerging Therapeutic Paradigms. - Abdel-Razeq H; Sharaf B (Current oncology (Toronto, Ont.), 2026)